Mycoplasma are the cell wall deficient microorganisms. They are prokaryotes and contain unique cell membrane with sterols. Patients suffering from sickle cell disease and hemoglobinopathies are at high risk for mycoplasma infections. Mycoplasma species can cause serious chronic inflammatory diseases of the respiratory system, urogenital tract, and joints. The most common harmful species of mycoplasma for humans is M. pneumoniae. Rising pool of M. pneumoniae infected patients is driving the growth of the global mycoplasma testing market. An article published by the Centers for Disease Control and Prevention (2018), approximately 2 million cases of M. pneumoniae infections occur each year in the U.S. This has urged the demand for mycoplasma testing and contribute to the growth of the market. However, lack of awareness related to this infection and difficulty in the detection of mycoplasma species may hamper the growth of the market.

Increasing investment in R&D sector further boosting the growth of the global mycoplasma testing market

Mycoplasma species are resistant to antibiotics such as penicillin and cephalosporin. In this case, to provide accurate treatment in terms of treating mycoplasma infections, new researches are required. Therefore, various pharmaceutical companies are investing funds in R&D to develop new drugs along with advanced technology for mycoplasma testing. These factors are further contributing to the growth of mycoplasma testing market across the world.

PCR technology is likely to dominate the global market

Based on the technology segment, PCR holds the largest market share through the forecast period in the global mycoplasma testing market. This technology can detect nearly 8 species of mycoplasma in cell culture. This benefit results in the growth of the global mycoplasma testing market. Better speed, accuracy and flexibility of PCR is another factor contributing to high preference for PCR testing in this space.

North America expected to hold the largest market share in the global market

Geographically, the global mycoplasma testing is classified into North America, Europe, Asia Pacific, Central & South America, and Middle East & Africa. North America is expected to hold the largest revenue share through the forecast period owing to increasing investment in the healthcare industry associated with laboratory techniques and rising prevalence of pneumonia contribute to the growth of the global mycoplasma testing market. Asia Pacific is likely to be the fastest growing market for mycoplasma testing owing to growing population, adoption of technology in healthcare sector and increasing pollution driving the demand for mycoplasma testing across the region.

Key Market Players

• Thermo Fisher Scientific Inc.
• Charles River Laboratories International, Inc.
• Merck KGaA
• Lonza Group Ltd.
• F. Hoffmann-La Roche Ltd
• Bionique Testing Laboratories, Inc.
• ScienCell Research Laboratories, Inc.

Market Segments: Mycoplasma testing

• By technology
  • PCR
  • ELISA
  • Direct Assay
  • Indirect Assay
  • DNA Staining
  • Microbial Culture Techniques
  • Enzymatic Methods
  • Others
• By application
  • Cell Line Testing
  • Virus Testing
  • End of Production Cells Testing
  • Others
• By end users
  • Biopharmaceutical Companies
  • Cell Banks
  • CROs
  • Research and academia
• By Region
  • North America
    • US
    • Canada
  • Europe
    • Germany
    • France
    • UK
  • Asia Pacific
    • China
    • India
    • Japan
  • Middle East & Africa
    • UAE
    • South Africa
  • Central & South America
    • Brazil
    • Mexico

Key Sources

• Industry associations
• Company annual reports
• Research journals
• Company websites
• Key industry leaders
• Technology consultants
• Others

Key Questions Answered

• What are the key growth regions and countries?
• What are the important types and technologies being used?
• What are the market players doing, in terms of research and development?
• Which are the new products anticipated to enter this market, if any?
• What is the recent news, developments, mergers, or large value deals?
• Where will the industry go in the long run?

Key Stakeholders

• Mycoplasma testing instrument manufacturers
• Mycoplasma testing instrument vendors, distributors, and service providers
• Pharmaceutical and biotechnology companies
• Academic research institutes related to mycoplasma testing
• Contract research organizations